Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

525

Sector

Biotechnology & Medical Research

Calendar

2024-09-24 - R&D Webinar - Central Nervous System

Related indices

Russell 2000

More about the company

Quotes

Date	Price	Change	Volume
24-09-06	22.22 $	-4.43%	1,009,581
24-09-05	23.25 $	-3.04%	862,890
24-09-04	23.98 $	+4.67%	828,221
24-09-03	22.91 $	-3.86%	1,024,765

Delayed Quote Nasdaq, September 06, 2024 at 04:00 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

22.22USD

Average target price

47.29USD

Spread / Average Target

+112.81%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-06 EDT			5-day change	1st Jan Change
22.22 ^USD	-4.43%		-6.76%	-27.39%

Capitalization	2.76B 3.75B	P/E ratio 2024 *	-4.92x	P/E ratio 2025 *	-5.46x
Enterprise value	2.58B 3.5B	EV / Sales 2024 *	41.9x	EV / Sales 2025 *	19x
Free-Float	95.53%	Yield 2024 *	-	Yield 2025 *	-

Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	09-03	MT
Transcript : Arrowhead Pharmaceuticals, Inc. - Shareholder/Analyst Call	09-03
Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran	09-03	DJ
Arrowhead Pharmaceuticals Says Phase 3 Study of Plozasiran Met Primary Endpoint	09-03	MT
Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome	09-02	CI
Investors already know...	08-22
Analyst recommendations: Estee Lauder, Sentinelone, Snowflake, Wolfspeed, Admiral...	08-22
Arrowhead Pharmaceuticals to Advance Two Drug Candidates in Clinical Trials on Obesity	08-14	MT
Arrowhead Pharmaceuticals to Advance Two Treatments for Obesity, Metabolic Diseases	08-14	DJ
Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call	08-14
Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies	08-14	CI
Tech, Yen, and Jobs: Wall Street's triple play	08-09
Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...	08-09

Analyst recommendations: Estee Lauder, Sentinelone, Snowflake, Wolfspeed, Admiral...	08-22
Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...	08-09
Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...	07-23
HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating	07-05	MT
UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating	05-10	MT

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome	09-02	BU
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome	08-21	BU
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies	08-14	BU
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results	08-08	BU
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street	08-08	BU

Arrowhead Pharmaceuticals, Inc. Stock

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Valuation: Arrowhead Pharmaceuticals, Inc.

Chart: Arrowhead Pharmaceuticals, Inc.

Latest news: Arrowhead Pharmaceuticals, Inc.

Last Transcript: Arrowhead Pharmaceuticals, Inc.

Analysts' recommendations: Arrowhead Pharmaceuticals, Inc.

Press Releases: Arrowhead Pharmaceuticals, Inc.

News in other languages: Arrowhead Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Arrowhead Pharmaceuticals, Inc.

ETFs: Arrowhead Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Estee Lauder, Sentinelone, Snowflake, Wolfspeed, Admiral...	08-22
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...	08-09
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU. : CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...	07-23
GSK : licence pour un traitement expérimental de l'hépatite B	23-10-31
Dow Jones Industrial Average : Les valeurs à suivre à Wall Street	18-10-04

1 day	-4.43%
1 week	-6.76%
Current month	-6.76%
1 month	-14.04%
3 months	-7.07%
6 months	-33.57%
Current year	-27.39%

Director	Title	Age	Since
Christopher Anzalone CEO	Chief Executive Officer	54	07-11-30
Kenneth Myszkowski DFI	Director of Finance/CFO	57	08-12-31
Bruce Given COO	Chief Operating Officer	69	11-10-25

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.40%	0 M€	0.00%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.35%	0 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ARROWHEAD PHARMACEUTICALS, INC.	-4.43%	-6.76%	-25.69%	-66.26%	2.76B
REGENERON PHARMACEUTICALS, INC.	-1.66%	-4.49%	+36.21%	+69.09%	122B
VERTEX PHARMACEUTICALS INCORPORATED	-0.12%	-5.62%	+36.42%	+144.55%	121B
ARGENX SE	+0.27%	+4.17%	+0.60%	+72.60%	32.37B
BIONTECH SE	-0.23%	+1.95%	-25.13%	-73.25%	21.38B
BEIGENE, LTD.	-0.14%	-0.24%	-0.68%	-44.16%	20.33B
GENMAB A/S	-0.27%	-0.72%	-29.41%	-35.71%	17.58B
WUXI APPTEC CO., LTD.	-2.17%	-0.97%	-49.08%	-72.27%	15.54B
VAXCYTE, INC.	-0.46%	+38.16%	+120.17%	+341.90%	13.59B
SAREPTA THERAPEUTICS, INC.	-3.63%	-5.05%	+7.51%	+64.71%	12.29B
Average	-1.28%	+2.42%	+7.09%	+40.12%	37.88B
Weighted average by Cap.	-0.84%	-1.55%	+22.88%	+77.34%

	2024 *	2025 *
Net sales	61.6M 83.53M	151M 204M
Net income	-537M -728M	-504M -684M
Net Debt	-183M -248M	100M 136M

Manager	Title	Age	Since
Christopher Anzalone CEO	Chief Executive Officer	54	07-11-30
Mauro Ferrari BRD	Director/Board Member	64	10-08-18
Douglass Given CHM	Chairman	71	10-11-22